SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio" or the “Company”) today announced that the Company, together with Eagle Pharmaceuticals, Inc. (Headquarters: New Jersey, U.S.A., “Eagle”), the Company's licensor, jointly filed a complaint in the Tokyo District Court against Pfizer Japan Inc. (Headquarters: Tokyo, “Pfizer”) seeking remedies for the infringement of Eagle’s patents for TREAKISYM® injection solution 100mg/4mL (generic name: bendamustine hydrochloride hydrate, hereinafter “TREAKISYM®”).
